The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development (19 December 2012)

The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development (19 December 2012)

[at noodls] – Read the full announcement in PDF format Bagsværd, Denmark, 19 December 2012 – Novo Nordisk today announced the completion of the phase 3a programme for IDegLira, a fixed-ratio combination of insulin … more

View todays social media effects on NVO

View the latest stocks trending across Twitter. Click to view dashboard

See who Novo is hiring next, click here to view

Share this post